

Fabio Dardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2208563/publications.pdf>

Version: 2024-02-01

15
papers

291
citations

1307366

7
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

534
citing authors

#	ARTICLE	IF	CITATIONS
1	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2808-2817.	1.2	91
2	Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 <scp>ESC</scp>/<scp>ERS</scp> guidelines and insights for future changes. <i>European Journal of Heart Failure</i> , 2018, 20, 248-255.	2.9	85
3	Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. <i>European Respiratory Journal</i> , 2015, 46, 414-421.	3.1	44
4	Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. <i>International Journal of Cardiology</i> , 2017, 235, 67-72.	0.8	13
5	Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease. <i>European Heart Journal</i> , 2018, 39, 1265-1268.	1.0	11
6	Left Main Coronary Artery Extrinsic Compression in Patients With Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 319-321.	1.1	10
7	Pulmonary arterial hypertension: guidelines and unmet clinical needs. <i>Reumatismo</i> , 2021, 72, 228-246.	0.4	10
8	Thrombolysis in high-risk patients with acute pulmonary embolism: underuse of a life-saving treatment in the real-world setting. <i>European Heart Journal</i> , 2020, 41, 530-533.	1.0	5
9	Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 39-42.	1.0	4
10	A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines. <i>Open Heart</i> , 2021, 8, e001725.	0.9	3
11	Long-term outcomes after pulmonary endarterectomy. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 172-174.	0.6	3
12	Balloon pulmonary angioplasty after pulmonary thromboendarterectomy. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 192-194.	0.6	3
13	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 120-127.	0.6	3
14	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2460-2461.	1.2	1
15	Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 943-943.	2.9	0